이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

MRI to Measure Treatment With Antibiotics in Alzheimer's Disease (DARAD-MRI)

2011년 4월 5일 업데이트: St. Joseph's Healthcare Hamilton

Magnetic Resonance Imaging to Measure Treatment Effects of Doxycycline and Rifampicin in Alzheimer's Disease

Objectives:

To study the changes in brain structure and function using MRI scans in patients treated for Alzheimer's disease.

Methods:

A pilot study of treating Alzheimer's disease with antibiotics showed some promise that this treatment could delay the deterioration of the mind with this disease. This study is being replicated on a larger scale, providing a more definitive answer to this question. In addition to looking at changes of the mind (through cognitive tests), we would like to use MRI scans in these patients before and after treatment to study the structural changes and the chemical changes in the brain. This would provide a non-invasive look at the bran processes that protect the brain from the effect of Alzheimer's as well as confirming that the disease has been modified with treatment.

Impact:

The novel treatment of Alzheimer's with antibiotics has provided a potential breakthrough in the field. In addition to verifying changes in the brain, MRI scans can observe HOW this process could occur, thus opening doors to other new treatments for Alzheimer's and perhaps even cures.

연구 개요

상태

완전한

연구 유형

관찰

등록 (실제)

58

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Ontario
      • Hamilton, Ontario, 캐나다, L8N 4A6
        • St. Joseph's Healthcare

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

50년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

예

연구 대상 성별

모두

샘플링 방법

비확률 샘플

연구 인구

Participants in the DARAD Trial (Doxycycline and Rifampicin for Alzheimer's disease).

설명

Inclusion Criteria:

(DARAD Trial)

  1. Male or female aged 50 years or older.
  2. Diagnosis of dementia using standardized DSM IV criteria and probable Alzheimer's disease (NINCDS-ADRDA criteria).
  3. SMMSE score 14-26 inclusive.
  4. Patients who have a consistent caregiver who will accompany them to clinic visits, ensure medication compliance, monitor and report adverse events and sign informed consent for his or her own participation.
  5. Sufficient visual, hearing and communication skills to complete standardized testing in English.
  6. Patients or their legally acceptable representatives for personal care who sign informed consent.
  7. Otherwise healthy on physical examination and screening physical and laboratory testing.

Exclusion Criteria:

(DARAD Trial)

  1. Patients with neurodegenerative diseases such as Lewy Body dementia, Parkinson's disease, Fronto-temporal Dementia, Huntington's Chorea, Down's Syndrome or Creutzfeld Jacob Disease.
  2. Cognitive impairment which may be due to any of the following conditions:

    1. acute cerebral trauma, subdural hematoma, injuries from chronic trauma like boxing.
    2. Hypoxic cerebral damage e.g. post cardiac arrest, postanesthesia etc.
    3. Vitamin deficiency like B12 deficiency will be treated and stabilized for one month before patients will be randomized to the study. Patients taking B12 for more than one month can be included in the study.
    4. Infections like cerebral abscesses, herpes, neurosyphilis, meningitis or AIDS.
    5. Primary or metastatic cerebral neoplasia.
    6. Endocrine deficiencies like hypercalcemia, hypothyroidism, hyperparathyroidism, Cushing's syndrome, severe renal failure, poorly controlled diabetes mellitus, pituitary disease, etc.
    7. Mental retardation. If a patient has one of these conditions and in the opinion of the investigator this condition has stabilized and is not contributing to the decline in cognition then this patient may be included in the study after the steering committee has reviewed the situation and approved participation.
  3. Multi-infarct dementia or significant cerebrovascular disease as evidenced by a) stroke with deficit that may confound the assessment of cognitive function or b) multiple focal signs on exam indicative of multiple ischemic events or c) findings on CT or MRI scan that show multiple lacunar infarcts, extensive periventricular white matter lesion, an infarct in the angular gyrus, the thalamus, the basal forebrain, the anterior or posterior cerebral artery territory.
  4. Patients with significant intracranial pathology such as tumour or hydrocephalus confirmed by CT or MRI in the past two years. The CT or MRI must be repeated before inclusion if the patient has experienced significant loss of consciousness or other neurological signs or symptoms, step-wise deterioration or has sustained a significant head injury since the last scan was performed. Patients with loss of consciousness, transient ischemic attacks or drop attacks, may be considered if these did not occur in the preceding twelve months.
  5. Patients with the following co-existing medical conditions:

    1. History of epilepsy or convulsions.
    2. Clinically significant psychiatric conditions (based on DSM-IV criteria) like major depression, schizophrenia. A Cornell Scale for Depression in Dementia score of 12 or more out of 38.
    3. Moderate to severe behavioural disturbances,
    4. Clinically significant hepatic, renal, pulmonary, metabolic or endocrine diseases.
    5. History of drug or alcohol abuse in the year prior to enrolment.
    6. History of myasthenia gravis.
  6. Clinically significant cardiac disease such as:

    1. Cardiac surgery in the past six months.
    2. Unstable angina or poorly controlled congestive heart failure (NYHA III or IV).
    3. Uncontrolled hypertension with systolic pressure greater that 180 mmHg. or diastolic pressure greater that 110 mmHg.
  7. Patients taking anti-dementia treatments with the following exceptions: donepezil, galantamine, rivastigmine, memantine, ASA up to 650 mg OD, Vitamin E 400 i.u., multi B vitamins, Ginko biloba, Cox II inhibitors or statins. In all cases the dose should have been stable for three months or more, and not be expected to change for the duration of the trial.
  8. Patients enrolled in other clinical trials with investigational drugs.
  9. Patients taking long term antibiotics (more than one month in the past six months).
  10. Allergies to these antibiotics.

(MRI)

  1. Cardiac pacemaker or implantable defibrillator
  2. Cerebral aneurysm clip
  3. Neural stimulator (e.g. TENS-Unit)
  4. Any type of ear implant
  5. Ocular foreign body (e.g. metal shavings)
  6. Any implanted device (e.g. insulin pump, drug infusion device)
  7. Metal shrapnel or bullet.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

코호트 및 개입

그룹/코호트
제어
일반 컨트롤
Placebo
Subjects who received placebo in DARAD Trial
Doxycycline
Subjects who received doxycycline in DARAD Trial
Rifampicin
Subjects who received rifampicin in DARAD Trial
Doxycycline and Rifampicin
Subjects who received doxycycline and rifampicin in DARAD Trial

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
기간
Changes in MRI Pre Vs Post Treatment
기간: 1 Year
1 Year

2차 결과 측정

결과 측정
기간
Comparison of Normal Controls Vs Alzheimer's Disease using MRI
기간: 1 Year
1 Year

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Mohammed A Warsi, (Hon)BSc, MSc, MD, FRCP(C), McMaster University
  • 연구 책임자: Michael D Noseworthy, (Hon)BSc, MSc, PhD, St. Joseph's Hospital
  • 연구 책임자: William Molloy, MBBch, MRCP, FRCP(C), St. Peters Hospital

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작

2008년 6월 1일

기본 완료 (실제)

2010년 6월 1일

연구 완료 (실제)

2010년 6월 1일

연구 등록 날짜

최초 제출

2008년 6월 4일

QC 기준을 충족하는 최초 제출

2008년 6월 4일

처음 게시됨 (추정)

2008년 6월 6일

연구 기록 업데이트

마지막 업데이트 게시됨 (추정)

2011년 4월 6일

QC 기준을 충족하는 마지막 업데이트 제출

2011년 4월 5일

마지막으로 확인됨

2011년 4월 1일

추가 정보

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다